<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02761473</url>
  </required_header>
  <id_info>
    <org_study_id>1608M92621</org_study_id>
    <nct_id>NCT02761473</nct_id>
  </id_info>
  <brief_title>Cutaneous Mastocytosis in Children: Analysis of Somatic and Germline Mutations</brief_title>
  <official_title>Cutaneous Mastocytosis in Children: Analysis of Somatic and Germline Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pediatric mastocytosis is an orphan disease, which encompasses several clinically distinct&#xD;
      entities including solitary mastocytoma, urticaria pigmentosa, diffuse cutaneous mastocytosis&#xD;
      and the newly recognized mast cell activation syndrome. The most common form of pediatric&#xD;
      mastocytosis is cutaneous maculopapular mastocytosis (CMPM), also known as urticaria&#xD;
      pigmentosa (UP). There are significant knowledge gaps regarding the genetic basis of&#xD;
      pediatric mastocytosis and the functional activity of mast cells in this condition. The&#xD;
      Pediatric Dermatology and Pediatric Oncology services at the University of Minnesota Masonic&#xD;
      Children's Hospital are seeing significant growth in clinical volumes of pediatric&#xD;
      mastocytosis, including rare, familial cases. The aims of this study are to prospectively&#xD;
      explore germline risk for UP and to perform a mutational analysis to identify somatic&#xD;
      mutations, beyond those currently identified, in pediatric patients with UP.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Urticaria pigmentosa (UP) is a relatively common disorder in pediatric patients, and little&#xD;
      is known regarding the somatic and germline genetic variants associated with the disease. The&#xD;
      University of Minnesota Masonic Children's Hospital is a regional referral center for&#xD;
      pediatric patients with mast cell disorders. Collaborators on this study include several&#xD;
      University departments including: Pediatric Dermatology, Pediatric Oncology, the Biomedical&#xD;
      Genomics program, Lab Medicine and Pathology department. We hypothesize that because of&#xD;
      differences observed in the clinical behavior of pediatric- and adult-onset mast cell&#xD;
      disease, specifically UP, we will identify novel somatic gene variants in addition to c-KIT .&#xD;
      We further hypothesize that we will observe novel germline genetic variants in pediatric UP&#xD;
      distinct from what has previously been described in adults.&#xD;
&#xD;
      Specific Aims include the following:&#xD;
&#xD;
      Specific Aim 1: RNA Sequencing for Gene Expression and Mutation Analysis. Utilizing RNA&#xD;
      sequencing (RNA-Seq), we will perform paired lesional and peripheral blood sequencing in UP&#xD;
      cases to identify variation in gene expression and define novel somatic mutations associated&#xD;
      with pediatric UP.&#xD;
&#xD;
      Specific Aim 2: Exploration of Germline Risk. Utilizing single nucleotide polymorphism (SNP)&#xD;
      array, we will perform linkage analysis in UP cases and their unaffected family members to&#xD;
      identify germline genetic variants associated with UP.&#xD;
&#xD;
        1. Discordant sibling analysis: Children with UP and their unaffected siblings will be&#xD;
           compared to identify germline variants.&#xD;
&#xD;
        2. Identical twin and parent analysis: Identical infant twins with a severe UP phenotype&#xD;
           will be compared with their unaffected parents.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Actual">May 1, 2020</completion_date>
  <primary_completion_date type="Actual">October 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Family-Based</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>RNA sequencing</measure>
    <time_frame>1.5 years</time_frame>
    <description>Fresh tissue from lesional skin will be obtained for gene expression and mutational analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SNP microarray analysis</measure>
    <time_frame>1.5 years</time_frame>
    <description>SNP microarray analysis will be performed on DNA obtained from buccal swabs or whole blood samples. Samples from patients and unaffected family members will be compared.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">50</enrollment>
  <condition>Urticaria Pigmentosa</condition>
  <condition>Cutaneous Mastocytosis</condition>
  <arm_group>
    <arm_group_label>Patients with Urticaria Pigmentosa</arm_group_label>
    <description>This group will undergo skin biopsy, blood and buccal swab analyses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Family members of affected patients</arm_group_label>
    <description>This group will undergo blood and buccal swab analyses</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>skin biopsy</intervention_name>
    <description>A skin biopsy will be obtained from a typical UP lesion in affected patients</description>
    <arm_group_label>Patients with Urticaria Pigmentosa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood draw</intervention_name>
    <description>Blood will be obtained from subjects, parents and unaffected siblings</description>
    <arm_group_label>Patients with Urticaria Pigmentosa</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Buccal swabs, skin biopsy and blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with urticaria pigmentosa and first degree relatives&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Affected subject:&#xD;
&#xD;
        Subjects will be eligible to participate in the study if all of the following conditions&#xD;
        exist:&#xD;
&#xD;
          1. Clinical diagnosis of urticaria pigmentosa/cutaneous mastocytosis with representative&#xD;
             skin lesions&#xD;
&#xD;
          2. Age &lt;23 years&#xD;
&#xD;
          3. Capable of giving consent if 18 or older&#xD;
&#xD;
        Inclusion Criteria for Parent:&#xD;
&#xD;
          1. Over 16 years of age&#xD;
&#xD;
          2. Biologic parent to affected subject&#xD;
&#xD;
          3. Capable of providing consent&#xD;
&#xD;
        Inclusion Criteria for Sibling:&#xD;
&#xD;
        1. Biologic sibling to affected subject 2. Capable of giving consent if 18 or older&#xD;
&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Absence of skin findings representative of classic urticaria pigmentosa&#xD;
&#xD;
          2. Patients with primarily systemic mastocytosis&#xD;
&#xD;
          3. Unable or unwilling to participate in study procedures&#xD;
&#xD;
        Exclusion Criteria for Parent/Sibling:&#xD;
&#xD;
        1. Unable or unwilling to participate in study procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>23 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hartmann K, Escribano L, Grattan C, Brockow K, Carter MC, Alvarez-Twose I, Matito A, Broesby-Olsen S, Siebenhaar F, Lange M, Niedoszytko M, Castells M, Oude Elberink JNG, Bonadonna P, Zanotti R, Hornick JL, Torrelo A, Grabbe J, Rabenhorst A, Nedoszytko B, Butterfield JH, Gotlib J, Reiter A, Radia D, Hermine O, Sotlar K, George TI, Kristensen TK, Kluin-Nelemans HC, Yavuz S, HÃ¤gglund H, Sperr WR, Schwartz LB, Triggiani M, Maurer M, Nilsson G, Horny HP, Arock M, Orfao A, Metcalfe DD, Akin C, Valent P. Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma &amp; Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol. 2016 Jan;137(1):35-45. doi: 10.1016/j.jaci.2015.08.034. Epub 2015 Oct 21. Review.</citation>
    <PMID>26476479</PMID>
  </results_reference>
  <results_reference>
    <citation>Longley BJ Jr, Metcalfe DD, Tharp M, Wang X, Tyrrell L, Lu SZ, Heitjan D, Ma Y. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1609-14.</citation>
    <PMID>9990072</PMID>
  </results_reference>
  <results_reference>
    <citation>Fried AJ, Akin C. Primary mast cell disorders in children. Curr Allergy Asthma Rep. 2013 Dec;13(6):693-701. doi: 10.1007/s11882-013-0392-6. Review.</citation>
    <PMID>24150753</PMID>
  </results_reference>
  <results_reference>
    <citation>Fett NM, Teng J, Longley BJ. Familial urticaria pigmentosa: report of a family and review of the role of KIT mutations. Am J Dermatopathol. 2013 Feb;35(1):113-6. doi: 10.1097/DAD.0b013e31826330bf. Review.</citation>
    <PMID>22892471</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>March 15, 2016</study_first_submitted>
  <study_first_submitted_qc>May 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2016</study_first_posted>
  <last_update_submitted>August 19, 2020</last_update_submitted>
  <last_update_submitted_qc>August 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mastocytosis</mesh_term>
    <mesh_term>Mastocytosis, Cutaneous</mesh_term>
    <mesh_term>Mastocytoma</mesh_term>
    <mesh_term>Urticaria Pigmentosa</mesh_term>
    <mesh_term>Urticaria</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

